Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Objectives Breast cancer is a popular fatal malignant tumor for women with high of rates incidence and mortality. Development of the new approaches for breast cancer targeted diagnosis and chemotherapy is emergently needed by the current clinical practice, the important first step is finding a breas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnology letters 2021-01, Vol.43 (1), p.153-164
Hauptverfasser: Jin, Huijuan, Gao, Xiaojie, Xiao, Li, He, Huimin, Cheng, Sinan, Zhang, Caixia, Hou, Yifan, Song, Fengying, Su, Xiaorong, Gao, Qian, Lu, Zheng, Yang, Ruina, Song, Xigui, Yang, Jin, Duan, Wei, Hou, Yingchun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives Breast cancer is a popular fatal malignant tumor for women with high of rates incidence and mortality. Development of the new approaches for breast cancer targeted diagnosis and chemotherapy is emergently needed by the current clinical practice, the important first step is finding a breast cancer specifically binding molecule or fragment as early clinical indicators. Results By a phage-displayed peptide library, a 12-mer peptide, CSB1 was screened out using MCF-7 cells as the target. The consequently results under immunofluorescence and laser scanning confocal microscope (LSCM) indicated that CSB1 bound MCF-7 cells and breast cancer tissues specifically and sensitively with high affinity. Bioinformatics analysis suggested that the peptide CSB1 targets the 5-Lipoxygenase-Activating Protein (FLAP), which has been implicated in breast cancer progression and prognosis. Conclusions The peptide, CSB1 is of the potential as a candidate to be used for developing the new approaches of molecular imaging detection and targeting chemotherapy of breast cancer in the future.
ISSN:0141-5492
1573-6776
DOI:10.1007/s10529-020-03044-3